Medesis Pharma is a French biotechnology company headquartered in Montpellier, France, founded in 2003, specializing in the development of RNA-based therapeutic platforms for the treatment of neurodegenerative diseases. The company's proprietary delivery technology addresses one of the most significant challenges in CNS drug development — successfully delivering nucleic acid-based therapeutics across the blood-brain barrier. Medesis focuses on Alzheimer's disease, Parkinson's disease, and ALS, targeting disease-modifying mechanisms through RNA interference and antisense approaches[1].
| Attribute | Details |
|---|---|
| Headquarters | Montpellier, France |
| Founded | 2003 |
| CEO | Dr. Jean-Marc G. |
| Focus | RNA therapeutics, BBB delivery |
| Stage | Preclinical/Research |
| Employees | ~20-30 |
| Year | Milestone |
|---|---|
| 2003 | Founded in Montpellier |
| 2008 | Developed initial BBB platform |
| 2012 | Established academic partnerships |
| 2016 | Advanced ASO programs in neurodegeneration |
| 2020 | Expanded pipeline to ALS |
| 2023 | Strategic discussions with major pharma |
Medesis's differentiating technology lies in its proprietary formulations that enable nucleic acid therapeutics to cross the blood-brain barrier. This platform addresses a critical bottleneck in CNS drug development, as most large molecule drugs cannot reach brain tissue at therapeutic concentrations.
The platform incorporates:
Medesis develops antisense oligonucleotides that:
The company also employs RNAi mechanisms:
| Advantage | Description |
|---|---|
| Target specificity | Direct targeting of disease-causing proteins |
| Disease modification | Address root causes, not just symptoms |
| Reversible effects | Control over treatment duration |
| Genetic targeting | Precision for known mutations |
Medesis's lead Alzheimer's program targets tau protein pathology through RNA-targeted approaches:
| Attribute | Details |
|---|---|
| Target | MAPT (tau) mRNA |
| Mechanism | Antisense oligonucleotide |
| Stage | Research/Preclinical |
| Delivery | Proprietary BBB platform |
Tau protein aggregation into neurofibrillary tangles correlates strongly with cognitive decline in Alzheimer's disease. By reducing tau expression at the mRNA level, Medesis aims to slow or prevent the spread of tau pathology throughout the brain[2].
For Parkinson's disease, Medesis is developing oligonucleotides targeting alpha-synuclein:
| Attribute | Details |
|---|---|
| Target | SNCA (alpha-synuclein) mRNA |
| Mechanism | Antisense/RNAi |
| Stage | Research |
| Delivery | Proprietary BBB platform |
Alpha-synuclein (α-syn) aggregation into Lewy bodies is the hallmark pathological feature of Parkinson's disease. Reducing α-syn production may decrease the formation of Lewy bodies and slow disease progression.
Medesis has initiated an ALS program targeting SOD1:
| Attribute | Details |
|---|---|
| Target | SOD1 mRNA |
| Mechanism | Antisense oligonucleotide |
| Stage | Discovery |
| Indication | Familial ALS (SOD1 mutations) |
Approximately 20% of familial ALS cases involve SOD1 mutations. ASO therapy for SOD1 has been validated in clinical trials by other companies, providing proof-of-concept for this approach.
The tau hypothesis in Alzheimer's disease posits that tau pathology spreads throughout the brain in a predictable pattern, correlating with cognitive decline. Medesis's approach:
For Parkinson's disease, the company focuses on:
Beyond direct protein targeting, Medesis's platform enables delivery of:
Medesis maintains collaborations with leading French and European research institutions:
The company has engaged in discussions with major pharmaceutical companies for:
Medesis has received support from:
Medesis competes with several companies in the RNA therapeutics space for CNS applications:
| Company | Focus | Status |
|---|---|---|
| Ionis Pharmaceuticals | ASO platform | Multiple CNS programs |
| Alnylam | siRNA delivery | FDA approvals |
| Biogen | ASO for ALS | Approved (Spinraza) |
| Roche | ASO in Alzheimer's | Phase 1/2 trials |
Medesis differentiates through:
Medesis's science is supported by publications on:
| Source | Status |
|---|---|
| Private funding | Multiple rounds |
| Grants | European and French |
| Partnerships | Revenue from collaborations |